Dr. Wenchang Yu 余文昌
Chief Physician
Department of Oncology and Vascular Intervention, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Interventional treatment of malignant tumors, including liver cancer, soft tissue sarcoma, and gastrointestinal cancers with liver metastasis. Manages complications such as malignant obstructive jaundice, deep vein thrombosis, vena cava tumor thrombus, and tumor-related bleeding using techniques like TACE, TAI, RFA, and PEI.
Dr. Yu holds a PhD in Clinical Medicine from Sun Yat-sen University (2003). After working at the First Affiliated Hospital of Nanjing Medical University, Dr. Yu joined Fujian Cancer Hospital in 2004. With 17 years in interventional therapy, Dr. Yu has published 20 papers as first author and led a provincial research project on liver cancer treatment from 2006 to 2009.
Professional roles
- Youth Committee Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Member, Chinese Society of Clinical Oncology (CSCO) Branch, China Anti-Cancer Association
- Youth Committee Member, 6th Committee of Radiology Branch, Fujian Medical Association
- Member, Expert Pool for Medical Malpractice Technical Appraisal, 3rd Committee, Fujian Medical Association
Name order: in Chinese the family name comes first (Yu Wenchang). Papers usually list the name as Wenchang Yu or Yu W.
Selected publications
21 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Eur J Nucl Med Mol Imaging, 2026 (senior author): Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis. PubMed 42625053
- J Hepatocell Carcinoma, 2026 (first author): Salvage Yttrium-90 Transarterial Radioembolization Combined with Second-Line Molecular Targeted Agents and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Progressing After TACE-Based Combination Therapy: A Single-Center Real-World Study. PubMed 42936717
- Front Immunol, 2026 (senior author): Hepatic arterial infusion chemotherapy plus tyrosine kinase inhibitors with or without PD-1 inhibitors for advanced hepatocellular carcinoma with VP4 portal vein tumor thrombosis: a retrospective cohort study. PubMed 42245629
- Br J Hosp Med (Lond), 2024 (senior author): The Pretreatment Neutrophil-to-Lymphocyte Ratio as a Near-Term Prognostic Indicator in Patients with Locally Advanced Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy: A Propensity Score Matching Cohort Study. PubMed 39618219
- Cancer Immunol Immunother, 2023 (first author): Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study. PubMed 37566127
- Eur J Cancer, 2020 (senior author): Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study. PubMed 32497895
- Medicine (Baltimore), 2018 (first author): Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study. PubMed 29505026
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion